Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Dianthus Therapeutics, Inc. (DNTH) Healthcare & Pipeline Overview

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in the creation of innovative monoclonal antibodies. Their lead drug candidate, DNTH103, is undergoing Phase 1 clinical trials targeting autoimmune and inflammatory conditions, positioning the company within the competitive biotechnology landscape focused on novel therapeutic solutions.

What Is the Investment Thesis for DNTH?

Dianthus Therapeutics, Inc. presents a focused investment opportunity within the biotechnology sector, centered on its lead drug candidate, DNTH103. Currently in Phase 1 clinical trials, DNTH103 targets significant autoimmune and inflammatory diseases, including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company's high gross margin of 94.3% indicates potential for strong profitability upon successful commercialization. Key value drivers include the successful completion of clinical trials, regulatory approvals, and subsequent market penetration. Growth catalysts involve expanding clinical trials to additional indications and securing partnerships for late-stage development and commercialization. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the autoimmune and inflammatory disease market. The company's relatively small size (78 employees) and negative profit margin (-847.5%) highlight the inherent risks associated with early-stage biotechnology companies.

Based on FMP financials and quantitative analysis

DNTH Key Highlights

Market capitalization of $6.08B reflects investor confidence in Dianthus Therapeutics' potential.

• Gross margin of 94.3% indicates strong pricing power and efficient manufacturing processes.
• DNTH103 is in Phase 1 clinical trials, targeting significant autoimmune and inflammatory diseases.
• The company was founded in 2015, indicating a relatively young but focused organization.
• Beta of 0.21 suggests low volatility compared to the broader market.

Who Are DNTH's Competitors?

DNTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DNTH's Key Strengths?

Novel monoclonal antibody technology.

• Focus on unmet needs in autoimmune diseases.
• Experienced management team.
• Strong intellectual property position.

What Are DNTH's Weaknesses?

Early-stage clinical development.

• Reliance on a single drug candidate (DNTH103).
• Limited financial resources.
• Negative profit margin.

What Could Drive DNTH Stock Higher?

DNTH catalyst: Completion of Phase 1 clinical trials for DNTH103 in generalized myasthenia gravis (gMG) by Q4 2026.

• Initiation of Phase 2 clinical trials for DNTH103 in multifocal motor neuropathy (MMN) by Q1 2027.
• Enrollment of patients in Phase 1 clinical trials for DNTH103 in chronic inflammatory demyelinating polyneuropathy (CIDP).
• Publication of clinical trial data in peer-reviewed journals.

What Are the Key Risks for DNTH?

Negative return on equity (-1.8%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of DNTH103 to demonstrate efficacy in clinical trials.
• Unexpected safety issues or adverse events in clinical trials.
• Delays in regulatory approvals.
• Competition from established players in the autoimmune disease market.
• Dependence on a single drug candidate (DNTH103).

What Are the Growth Opportunities for DNTH?

• Expansion of DNTH103 Clinical Trials: Dianthus has the opportunity to expand the clinical trials for DNTH103 to include additional autoimmune and inflammatory diseases beyond the current targets of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. This expansion could significantly increase the potential market size for DNTH103, addressing a broader range of patient populations with unmet medical needs. The timeline for this expansion would depend on the successful completion of the ongoing Phase 1 trials and subsequent regulatory approvals.
• Strategic Partnerships and Collaborations: Dianthus can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of DNTH103. These partnerships could provide access to additional funding, expertise, and resources, enabling Dianthus to navigate the complex regulatory landscape and effectively market its products. The timeline for securing these partnerships would depend on the progress of clinical trials and the attractiveness of DNTH103 to potential partners.
• Advancement of Pipeline Programs: Dianthus has the opportunity to advance its pipeline programs beyond DNTH103, developing additional monoclonal antibodies targeting other autoimmune and inflammatory diseases. This would diversify the company's product portfolio and reduce its reliance on a single drug candidate. The timeline for advancing these pipeline programs would depend on the availability of funding and the success of preclinical and clinical studies.
• Geographic Expansion: Dianthus can expand its geographic reach beyond the United States, targeting markets in Europe, Asia, and other regions with significant unmet needs for autoimmune and inflammatory disease treatments. This expansion would require navigating different regulatory environments and establishing distribution networks in new markets. The timeline for geographic expansion would depend on the availability of resources and the attractiveness of different markets.
• Personalized Medicine Approaches: Dianthus can explore personalized medicine approaches, tailoring its treatments to individual patients based on their genetic profiles and other biomarkers. This would require developing diagnostic tools to identify patients who are most likely to respond to DNTH103 and other monoclonal antibodies. The timeline for implementing personalized medicine approaches would depend on the progress of research in this area and the availability of relevant diagnostic tools.

What Threats Does DNTH Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established players.
• Patent challenges.

What Are DNTH's Competitive Advantages?

• Proprietary monoclonal antibody technology.
• Strong intellectual property protection.
• Focus on specific autoimmune disease targets.
• Expertise in antibody engineering.

What Does DNTH Do?

Dianthus Therapeutics, Inc., established in 2015 and headquartered in New York City, is a clinical-stage biotechnology company dedicated to the design, development, and delivery of novel monoclonal antibodies. The company focuses on addressing the unmet needs of individuals suffering from severe autoimmune and inflammatory diseases. Dianthus's primary asset, DNTH103, is currently undergoing Phase 1 clinical trials. These trials are specifically targeting patients with generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's core strategy revolves around leveraging its expertise in antibody engineering to create highly selective and potent therapeutics. By focusing on well-validated biological targets, Dianthus aims to improve treatment outcomes and enhance the quality of life for patients with debilitating autoimmune and inflammatory conditions. Dianthus operates with a team of 78 employees, reflecting a focused and agile approach to drug development. The company's location in New York City provides access to a rich ecosystem of scientific talent, research institutions, and financial resources, supporting its mission to advance innovative therapies.

What Products and Services Does DNTH Offer?

• Designs novel monoclonal antibodies.
• Develops monoclonal antibodies for autoimmune diseases.
• Delivers monoclonal antibodies to patients.
• Focuses on severe autoimmune and inflammatory diseases.
• Conducts Phase 1 clinical trials for DNTH103.
• Targets generalized myasthenia gravis (gMG).
• Targets multifocal motor neuropathy (MMN).
• Targets chronic inflammatory demyelinating polyneuropathy (CIDP).

How Does DNTH Make Money?

• Develops and patents novel monoclonal antibodies.
• Out-licenses or partners for late-stage development and commercialization.
• Generates revenue through milestone payments and royalties.

What Industry Does DNTH Operate In?

Dianthus Therapeutics, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for autoimmune and inflammatory disease treatments is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Key trends include the development of personalized medicine, the rise of biologics and biosimilars, and the increasing importance of data analytics in drug discovery and development. Dianthus's focus on monoclonal antibodies positions it within a segment of the market that is experiencing rapid growth and innovation.

Who Are DNTH's Key Customers?

• Patients with severe autoimmune diseases.
• Hospitals and clinics.
• Pharmaceutical companies (potential partners).

Company Profile

Dianthus Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Marino Garcia. DNTH has traded publicly since 2018.

Return on equity for Dianthus Therapeutics, Inc. stands at -1.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 29.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.3%, the inverse of the P/E and a quick read on earnings relative to price.

DNTH Valuation & Market Position

With a $6.08B market cap, Dianthus Therapeutics, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $98.00 to $158.00, with a consensus of $126.83. At the current price of $108.71, that implies approximately 17% upside potential. Relative to its peer group, DNTH's quantitative score of 26/100 is below the peer average of 88/100.

Quarterly Financial Performance: Dianthus Therapeutics, Inc.

Revenue for Dianthus Therapeutics, Inc. came in at $761K during Q2 FY2026, a 64.4% improvement versus the preceding quarter. The company recorded a net loss of $50.2M, with diluted EPS of $-0.90. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, DNTH averaged $-0.03 in diluted EPS.

Dianthus Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 87.38 places it in the safe zone, indicating low near-term bankruptcy risk.

Dianthus Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 7.0% below estimates on average.

Over the past six months, Dianthus Therapeutics, Inc. insiders filed 100 SEC Form 4 transactions — 69 sales and 31 purchases. On net that is roughly 419K shares disposed (about $40.7M), a signal worth weighing alongside the fundamentals.

DNTH Financials

DNTH Latest News

DNTH Analyst Consensus

DNTH MoonshotScore

DNTH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources